2017-03-15,Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection Of Mesoblast's Cell Therapy
2017-03-07,FDA Grants Fast Track Designation For Mesoblast's Cell Therapy In Children With Acute Graft Versus Host Disease
2017-02-26,Mesoblast Presents Corporate Update And Financial Results For The Half Year Period Ended December 31, 2016
2017-02-24,Mesoblast To Host Second Quarter And First Half Financial Results Conference Call And Webcast
2017-02-15,Durable Responses And Sustained Low Disease Activity Over Nine Months After A Single Dose Of Mesoblast Cell Therapy In Rheumatoid Arthritis Patients Resistant To Anti-TNF Agents
2017-02-13,Published Study Results Show That Mesoblast Cells Administered Intravenously Significantly Ameliorate Joint Disease In Model Of Early Rheumatoid Arthritis
2017-01-31,Mesoblast Director Recognized By Peers For Cardiovascular Leadership
2017-01-11,Mesoblast To Present At 35th Annual J.P. Morgan Healthcare Conference
2017-01-09,Mesoblast Receives A$29.6 Million Following Share Issue To Mallinckrodt
2016-12-22,Mesoblast And Mallinckrodt Enter Into Equity Purchase Agreement To Exclusively Negotiate Development And Commercialization Of Mesoblast's Cell Therapy Products For Chronic Low Back Pain And Acute Graft Versus Host Disease
2016-12-09,United States Congress Legislates New Accelerated Approval Pathway For Regenerative Advanced Therapies
2016-12-06,MD Anderson Cancer Center And National Institutes Of Health To Fund Clinical Trial Combining Two Proprietary Mesoblast Technologies For Rapid Engraftment Of Stem Cell Transplants In Cancer Patients
2016-11-14,Mesoblast Provides Corporate Update And Financial Results For The First Quarter Ended September 30, 2016
2016-11-14,Mesoblast Announces Successful Interim Futility Analysis In Phase 3 Trial For Acute Graft Versus Host Disease
2016-11-09,Mesoblast To Host First Quarter Financial Results Conference Call And Webcast
2016-10-18,Mesoblast Named 2016 Cell Therapy Company Of The Year At Frost & Sullivan Asia Pacific Best Practices Awards
2016-10-12,Mesoblast Japan Strategy Highlighted At Australia-Japan Business Council Annual Meeting
2016-10-06,Phase 2 Trial Results Of Mesoblast's Cell Therapy In Diabetic Kidney Disease Published
2016-09-29,Mesoblast Enters Oversold Territory (MESO)
2016-09-01,Mesoblast Appoints Bill Burns, Former Chief Executive Of Roche Pharmaceuticals, As Vice Chairman
2016-08-24,Mesoblast Reports Financial Results And Operational Highlights For The Three Months And For The Year Ended 30 June 2016
2016-08-19,Mesoblast To Host Fourth Quarter And Full Year Financial Results Conference Call And Webcast
2016-08-17,Mesoblast Strengthens Key United States Patent Portfolio For The Treatment Of Rheumatic Diseases
2016-08-08,Phase 2 Trial Results Of Mesoblast's Cell Therapy Show Dose-Related Improvements In Biologic Refractory Rheumatoid Arthritis
2016-08-01,Mesoblast's Full 24-Month Trial Results For Chronic Low Back Pain Presented At Spine Intervention Society Annual Meeting, Receive Award For Best Basic Science
2016-07-01,Mesoblast Provides Update On Heart Failure Trial And Funding Of Clinical Operations
2016-06-13,Mesoblast Provides Update On Global Heart Failure Program
2016-05-31,Ratings Changes Today
2016-05-09,Mesoblast Reports Financial Results For Period Ended 31 March 2016 And Provides Corporate Update
2016-05-06,Mesoblast To Host Third Quarter And Nine Months Financial Results Conference Call And Webcast
2016-05-05,Mesoblast is Now Oversold (MESO)
2016-04-01,Mesoblast Cell Therapy Shows Disease Modifying Effects On Knee Osteoarthritis
2016-03-24,Key United States Patent Granted For Cell-Based Treatment Of Rheumatoid Arthritis And Other Rheumatic Conditions
2016-03-17,New Mesoblast Cell Targeting Technology Shows Potential To Induce Durable Reversal Of Type 1 Diabetes
2016-02-24,First Allogeneic Cell Therapy Product Launched In Japan By Mesoblast Licensee
2016-02-22,Mesoblast's Cell Therapy Increases Survival In Children With Acute Graft Versus Host Disease
2016-02-16,Mesoblast Reports On First Half And Second Quarter Financial Results
2016-02-16,Mesoblast Cell Therapy Shows Clinical Benefit In First Cohort Of Patients With Biologic Refractory Rheumatoid Arthritis
2016-02-11,Mesoblast To Host Second Quarter And First Half Financial Results Conference Call And Webcast
2016-01-11,Phase 3 Heart Failure Trial Size To Be Substantially Reduced Following FDA Discussions
2016-01-07,Mesoblast To Present At The 34th Annual J. P. Morgan Healthcare Conference
2015-12-16,Mesoblast Provides Strategic Update And Reports On First Quarter Financial Results
2015-12-15,Mesoblast To Host First Quarter Financial Results Conference Call And Webcast On 16 December 2015
2015-11-27,Mesoblast's Japan Licensee Receives Pricing For TEMCELL® HS Inj. For Treatment Of Acute Graft Versus Host Disease
2015-11-23,Mesoblast Investor Update
,
,
,
,
